The DOI matches its Crossref record; 219 of the 219 references it cites were found in a registry or an index.
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Abstract
The obesity epidemic is closely associated with the rising prevalence and severity of nonalcoholic fatty liver disease (NAFLD): obesity has been linked not only with simple steatosis (SS), but also with advanced disease, i.e., nonalcoholic steatohepatitis (NASH), NASH-related cirrhosis and hepatocellular carcinoma. As a consequence, apart from increasing all-cause mortality, obesity seems to increase liver-specific mortality in NAFLD patients. Given the lack of approved pharmacological interventions for NAFLD, targeting obesity is a rational option for its management. As the first step, lifestyle modification (diet and exercise) is recommended, although it is difficult to achieve and sustain. When the first step fails, adding pharmacotherapy is recommended. Several anti-obesity medications have been investigated in NAFLD (e.g., orlistat, glucagon-like peptide-1 analogs), other anti-obesity medications have not been investigated (e.g., lorcaserin, phentermine hydrochloric, phentermine/topiramate and naltrexone/bupropion), whereas some medications with weight-lowering efficacy have not been approved for obesity (e.g., sodium-glucose cotransporter-2 inhibitors, farnesoid X receptor ligands). If the combination of lifestyle modification and pharmacotherapy also fails, then bariatric surgery should be considered in selected morbidly obese individuals. This review summarizes best evidence linking obesity with NAFLD and presents related therapeutic options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. C., Biryukov, S., Abbafati, C., Abera, S. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60460-8 · Cited by 11,952
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 6×
“Owing to their weight loss properties, liraglutide (3 mg subcutaneously QD) has been approved as anti-obesity medication since 2014 and 2015 in the USA and Europe, respectively.”
BackgroundInfluentialGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“Moreover, since the early stages of NAFLD usually disclose no obvious symptoms, the prevalence of obesity-driven NAFLD and followingmorbidity can be considered oneof themain health crises of the next decade [11,12].”
BackgroundEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Finucane, M. M., Stevens, G. A., Cowan, M. J., Danaei, G., Lin, J. K., Paciorek, C. J., Singh, G. M., Gutierrez, H. R., Lu, Y., Bahalim, A. N., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62037-5 · Cited by 4,050 · cited 2×
“5 billion adults worldwide are overweight, among them about 200 million men and 300 million women are obese [1].”
BackgroundChalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Vernon, G., Baranova, A., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,074
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Nonalcoholic Fatty Liver Disease: A Systematic Review
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,267
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Szczepaniak, L. S., Nurenberg, P., Leonard, D., Browning, J. D., Reingold, J. S., Grundy, S., Hobbs, H. H., & Dobbins, R. L. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,562
Wang, Y., Beydoun, M. A., Liang, L., Caballero, B., & Kumanyika, S. K. (2008) · Obesity · doi:10.1038/oby.2008.351 · Cited by 1,518
Powell, E. E., Cooksley, G. W. E., Hanson, R., Searle, J., Halliday, J. W., & Powell, L. W. (1990) · Hepatology · doi:10.1002/hep.1840110114 · Cited by 1,473
Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., Carucci, P., Musso, A., De Paolis, P., Capussotti, L., Salizzoni, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34168 · Cited by 1,439
Dixon, J. B., Bhathal, P. S., & O'Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,360
Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy
Bellentani, S., Saccoccio, G., Masutti, F., Crocè, L. S., Brandi, G., Sasso, F., Cristanini, G., & Tiribelli, C. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-2-200001180-00004 · Cited by 1,265
Bedogni, G., Miglioli, L., Masutti, F., Tiribelli, C., Marchesini, G., & Bellentani, S. (2005) · Hepatology · doi:10.1002/hep.20734 · Cited by 1,263
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.
Wanless, I. R., & Lentz, J. S. (1990) · Hepatology · doi:10.1002/hep.1840120505 · Cited by 1,191
Cryptogenic Cirrhosis: Clinical Characterization and Risk Factors for Underlying Disease
Caldwell, S. H., Oelsner, D. H., Iezzoni, J. C., Hespenheide, E. E., Battle, E. H., & Driscoll, C. J. (1999) · Hepatology · doi:10.1002/hep.510290347 · Cited by 1,143
The economic burden of obesity worldwide: a systematic review of the direct costs of obesity
Withrow, D., & Alter, D. A. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00712.x · Cited by 1,083 · cited 1×
“higher than those of normal weight individuals [6].”
BackgroundLiver fibrosis in overweight patients
Ratziu, V., Giral, P., Charlotte, F., Bruckert, E., Thibault, V., Theodorou, I., Khalil, L., Turpin, G., Opolon, P., & Poynard, T. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70364-7 · Cited by 973
Genetics and epigenetics of NAFLD and NASH: Clinical impact
Eslam, M., Valenti, L., & Romeo, S. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.003 · Cited by 971
The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An Update
El-Serag, H. B., Davila, J. A., Petersen, N. J., & McGlynn, K. A. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00009 · Cited by 943
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931 · cited 2×
“Furthermore, the combination of exenatide and insulin glargine was shown to decrease LFTs and reverse hepatic steatosis (evaluated by ultrasonography) more effectively than the intensive insulin therapy (insulin glargine and insulin aspart) in another 4-month RCT with obese with T2DM and NAFLD [173].”
BackgroundAdams, L. A., Sanderson, S., Lindor, K. D., & Angulo, P. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.012 · Cited by 911
Anderson, E. L., Howe, L. D., Jones, H. E., Higgins, J. P. T., Lawlor, D. A., & Fraser, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140908 · Cited by 898
Harrison, S. A., Oliver, D., Arnold, H. L., Gogia, S., & Neuschwander-Tetri, B. A. (2008) · Gut · doi:10.1136/gut.2007.146019 · Cited by 869
Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients
Lassailly, G., Caiazzo, R., Buob, D., Pigeyre, M., Verkindt, H., Labreuche, J., Raverdy, V., Leteurtre, E., Dharancy, S., Louvet, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.014 · Cited by 762
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2016) · Diabetologia · doi:10.1007/s00125-016-3902-y · Cited by 683
Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0165 · Cited by 662
Hepatic histology in obese patients undergoing bariatric surgery
Machado, M., Marques-Vidal, P., & Cortez-Pinto, H. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.06.013 · Cited by 583
Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
Mota, M., Banini, B. A., Cazanave, S. C., & Sanyal, A. J. (2016) · Metabolism · doi:10.1016/j.metabol.2016.02.014 · Cited by 570
Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study
Poonawala, A., Nair, S. P., & Thuluvath, P. J. (2000) · Hepatology · doi:10.1053/jhep.2000.17894 · Cited by 569
JSG-NAFLD, Eguchi, Y., Hyogo, H., Ono, M., Mizuta, T., Ono, N., Fujimoto, K., Chayama, K., & Saibara, T. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0533-z · Cited by 551
Leoni, S., Tovoli, F., Napoli, L., Serio, I., Ferri, S., & Bolondi, L. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i30.3361 · Cited by 539
Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis
Keating, S. E., Hackett, D. A., George, J., & Johnson, N. A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.023 · Cited by 537
Heber, D., Greenway, F. L., Kaplan, L. M., Livingston, E., Salvador, J., & Still, C. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2128 · Cited by 521
Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-analysis
Mummadi, R. R., Kasturi, K. S., Chennareddygari, S., & Sood, G. K. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.08.012 · Cited by 511
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review
Hashida, R., Kawaguchi, T., Bekki, M., Omoto, M., Matsuse, H., Nago, T., Takano, Y., Ueno, T., Koga, H., George, J., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.023 · Cited by 509 · cited 2×
“However, intensity and energy consumption needed to achieve a similar result was lower for resistance than for aerobic exercise, thereby possibly rendering the former more suitable for NAFLD patients unwilling to participate in aerobic exercise or those with poor cardiorespiratory fitness [141].”
BackgroundCaldwell, S. H., & Crespo, D. M. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.02.013 · Cited by 501
Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies
Larsson, S. C., & Wolk, A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603932 · Cited by 495
Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty
Luyckx, F., Desaive, C., Thiry, A., Dewé, W., Scheen, A., Gielen, J., & Lefèbvre, P. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800571 · Cited by 489
Harrison, S. A., Fecht, W., Brunt, E. M., & Neuschwander‐Tetri, B. A. (2009) · Hepatology · doi:10.1002/hep.22575 · Cited by 470 · cited 2×
“therapy with the combination of vitamin E and orlistat (120 mg TID) failed to show an additive effect of orlistat on NAFLD [156].”
BackgroundNatural history of nonalcoholic steatohepatitis: A longitudinal study of repeat liver biopsies
Fassio, E., �lvarez, E., Dom�nguez, N., Landeira, G., & Longo, C. (2004) · Hepatology · doi:10.1002/hep.20410 · Cited by 469
Ma, C., Avenell, A., Bolland, M., Hudson, J., Stewart, F., Robertson, C., Sharma, P., Fraser, C., & MacLennan, G. (2017) · BMJ · doi:10.1136/bmj.j4849 · Cited by 464
Beste, L. A., Leipertz, S. L., Green, P. K., Dominitz, J. A., Ross, D., & Ioannou, G. N. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.056 · Cited by 459
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456
Kojima, S.-I., Watanabe, N., Numata, M., Ogawa, T., & Matsuzaki, S. (2003) · Journal of Gastroenterology · doi:10.1007/s00535-003-1178-8 · Cited by 455
Li, L., Liu, D. ‐., Yan, H. ‐., Wang, Z. ‐., Zhao, S. ‐., & Wang, B. (2016) · Obesity Reviews · doi:10.1111/obr.12407 · Cited by 439
Orlistat-Associated Adverse Effects and Drug Interactions: A Critical Review
Filippatos, T. D., Derdemezis, C. S., Gazi, I. F., Nakou, E. S., Mikhailidis, D. P., & Elisaf, M. S. (2008) · Drug Safety · doi:10.2165/00002018-200831010-00005 · Cited by 434
Epidemiology and natural history of non-alcoholic fatty liver disease
Fazel, Y., Koenig, A. B., Sayiner, M., Goodman, Z. D., & Younossi, Z. M. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.012 · Cited by 433
Amarapurkar, D. N., Hashimoto, E., Lesmana, L. A., Sollano, J. D., Chen, P., Goh, K., & NAFLD, F. T. A. W. P. O. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05042.x · Cited by 395
Shimizu, M., Suzuki, K., Kato, K., Jojima, T., Iijima, T., Murohisa, T., Iijima, M., Takekawa, H., Usui, I., Hiraishi, H., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13520 · Cited by 390
Lee, Y., Doumouras, A. G., Yu, J., Brar, K., Banfield, L., Gmora, S., Anvari, M., & Hong, D. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.10.017 · Cited by 371
Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease
Satapathy, S., & Sanyal, A. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562943 · Cited by 371
Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?
Nair, S., Mason, A., Eason, J., Loss, G., & Perrillo, R. P. (2002) · Hepatology · doi:10.1053/jhep.2002.33713 · Cited by 348
Adipokines in nonalcoholic fatty liver disease
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2015.11.006 · Cited by 348
Self-citationHistological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients
Leung, J. C., Loong, T. C., Wei, J. L., Wong, G. L., Chan, A. W., Choi, P. C., Shu, S. S., Chim, A. M., Chan, H. L., & Wong, V. W. (2017) · Hepatology · doi:10.1002/hep.28697 · Cited by 348
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
Thomas, M. C., & Cherney, D. Z. I. (2018) · Diabetologia · doi:10.1007/s00125-018-4669-0 · Cited by 348
Imajo, K., Fujita, K., Yoneda, M., Nozaki, Y., Ogawa, Y., Shinohara, Y., Kato, S., Mawatari, H., Shibata, W., Kitani, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.05.012 · Cited by 341
Younossi, Z., & Henry, L. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.005 · Cited by 334 · cited 1×
“Moreover, since the early stages of NAFLD usually disclose no obvious symptoms, the prevalence of obesity-driven NAFLD and followingmorbidity can be considered oneof themain health crises of the next decade [11,12].”
BackgroundNonalcoholic Fatty Liver Disease: The Pathogenetic Roles of Insulin Resistance and Adipocytokines
Polyzos, S., Kountouras, J., & Zavos, C. (2009) · Current Molecular Medicine · doi:10.2174/156652409787847191 · Cited by 327
Self-citationObesity is an independent risk factor for clinical decompensation in patients with cirrhosis
Berzigotti, A., Garcia-Tsao, G., Bosch, J., Grace, N. D., Burroughs, A. K., Morillas, R., Escorsell, A., Garcia-Pagan, J. C., Patch, D., Matloff, D. S., et al. (2011) · Hepatology · doi:10.1002/hep.24418 · Cited by 325
Predictors of Nonalcoholic Steatohepatitis and Advanced Fibrosis in Morbidly Obese Patients
Ong, J. P., Elariny, H., Collantes, R., Younoszai, A., Chandhoke, V., Reines, H. D., Goodman, Z., & Younossi, Z. M. (2005) · Obesity Surgery · doi:10.1381/0960892053576820 · Cited by 322
Zelber–Sagi, S., Kessler, A., Brazowsky, E., Webb, M., Lurie, Y., Santo, M., Leshno, M., Blendis, L., Halpern, Z., & Oren, R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.02.004 · Cited by 317
Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis
Polyzos, S. A., Toulis, K. A., Goulis, D. G., Zavos, C., & Kountouras, J. (2011) · Metabolism · doi:10.1016/j.metabol.2010.09.003 · Cited by 311
Self-citationEpidemiology of Obesity in Adults: Latest Trends
Inoue, Y., Qin, B., Poti, J., Sokol, R., & Gordon-Larsen, P. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0317-8 · Cited by 308 · cited 1×
“nal data introducingmeasured anthropometry to capture trends in USA adult obesity for the same people over time [3].”
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
Lonardo, A., Nascimbeni, F., Targher, G., Bernardi, M., Bonino, F., Bugianesi, E., Casini, A., Gastaldelli, A., Marchesini, G., Marra, F., et al. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.01.147 · Cited by 306
Stepanova, M., Rafiq, N., & Younossi, Z. M. (2010) · Gut · doi:10.1136/gut.2010.213553 · Cited by 303
Bariatric surgery for non-alcoholic steatohepatitis in obese patients
Chavez-Tapia, N. C., Tellez-Avila, F. I., Barrientos-Gutierrez, T., Mendez-Sanchez, N., Lizardi-Cervera, J., & Uribe, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007340.pub2 · Cited by 297
Nonalcoholic Fatty Liver Disease in Severely Obese Subjects
Gholam, P. M., Flancbaum, L., Machan, J. T., Charney, D. A., & Kotler, D. P. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.01041.x · Cited by 296
Ito, D., Shimizu, S., Inoue, K., Saito, D., Yanagisawa, M., Inukai, K., Akiyama, Y., Morimoto, Y., Noda, M., & Shimada, A. (2017) · Diabetes Care · doi:10.2337/dc17-0518 · Cited by 279
The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease
Polyzos, S. A., Kountouras, J., Zavos, C., & Tsiaousi, E. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01176.x · Cited by 277
Self-citationKatsagoni, C. N., Georgoulis, M., Papatheodoridis, G. V., Panagiotakos, D. B., & Kontogianni, M. D. (2017) · Metabolism · doi:10.1016/j.metabol.2016.12.006 · Cited by 270
Dutour, A., Abdesselam, I., Ancel, P., Kober, F., Mrad, G., Darmon, P., Ronsin, O., Pradel, V., Lesavre, N., Martin, J. C., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12680 · Cited by 262
Mittal, S., Sada, Y. H., El-Serag, H. B., Kanwal, F., Duan, Z., Temple, S., May, S. B., Kramer, J. R., Richardson, P. A., & Davila, J. A. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.08.013 · Cited by 261
Padwal, R., Klarenbach, S., Wiebe, N., Birch, D., Karmali, S., Manns, B., Hazel, M., Sharma, A. M., & Tonelli, M. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00866.x · Cited by 260
Bower, G., Toma, T., Harling, L., Jiao, L. R., Efthimiou, E., Darzi, A., Athanasiou, T., & Ashrafian, H. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1691-x · Cited by 256
Circulating leptin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Polyzos, S. A., Aronis, K. N., Kountouras, J., Raptis, D. D., Vasiloglou, M. F., & Mantzoros, C. S. (2016) · Diabetologia · doi:10.1007/s00125-015-3769-3 · Cited by 248 · cited 1×
“Although this hypothesis has not been as yet validated in humans, lower leptin levels were observed in controls, higher in SS patients and even higher in NASH patients [49], which may possibly imply an unfavorable effect of leptin on the disease progression.”
BackgroundSelf-citationMonami, M., Nreu, B., Scatena, A., Cresci, B., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12926 · Cited by 243
Leptin in nonalcoholic fatty liver disease: A narrative review
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.012 · Cited by 235 · cited 1×
“In this regard, leptin appears to exhibit an antisteatotic action at the early disease stages, but it may also promote hepatic inflammation and fibrosis, when the disease progresses [47,48].”
BackgroundSelf-citationSookoian, S., & Pirola, C. J. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14112 · Cited by 230 · cited 2×
“Given the above, a meta-analysis showed that lean patients with NAFLD had a worse metabolic profile than lean individuals without NAFLD, including largerwaist circumference and higher IR, thus sharing common MetS risk factors with obese NAFLD patients [80].”
BackgroundResultFracanzani, A. L., Petta, S., Lombardi, R., Pisano, G., Russello, M., Consonni, D., Di Marco, V., Cammà, C., Mensi, L., Dongiovanni, P., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.045 · Cited by 230
Petit, J.-M., Cercueil, J.-P., Loffroy, R., Denimal, D., Bouillet, B., Fourmont, C., Chevallier, O., Duvillard, L., & Vergès, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2775 · Cited by 227
Caiazzo, R., Lassailly, G., Leteurtre, E., Baud, G., Verkindt, H., Raverdy, V., Buob, D., Pigeyre, M., Mathurin, P., & Pattou, F. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000945 · Cited by 226
Kim, D., Li, A. A., Gadiparthi, C., Khan, M. A., Cholankeril, G., Glenn, J. S., & Ahmed, A. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.008 · Cited by 223
Addy, C. L., Gavrila, A., Tsiodras, S., Brodovicz, K., Karchmer, A. W., & Mantzoros, C. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020795 · Cited by 220
Self-citationAthyros, V. G., Alexandrides, T. K., Bilianou, H., Cholongitas, E., Doumas, M., Ganotakis, E. S., Goudevenos, J., Elisaf, M. S., Germanidis, G., Giouleme, O., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.02.014 · Cited by 219
Self-citationPalekar, N. A., Naus, R., Larson, S. P., Ward, J., & Harrison, S. A. (2006) · Liver International · doi:10.1111/j.1478-3231.2005.01209.x · Cited by 216
Zimmermann, E., Gamborg, M., Holst, C., Baker, J. L., Sørensen, T. I. A., & Berentzen, T. L. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-006998 · Cited by 213
Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index
Pang, Q. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i5.1650 · Cited by 210
Orci, L. A., Gariani, K., Oldani, G., Delaune, V., Morel, P., & Toso, C. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.04.036 · Cited by 209
Metabolically Healthy Obesity and the Development of Nonalcoholic Fatty Liver Disease
Chang, Y., Jung, H.-S., Cho, J., Zhang, Y., Yun, K. E., Lazo, M., Pastor-Barriuso, R., Ahn, J., Kim, C.-W., Rampal, S., et al. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.178 · Cited by 209
Adipose tissue, obesity and non-alcoholic fatty liver disease
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2017) · Minerva Endocrinology · doi:10.23736/s0391-1977.16.02563-3 · Cited by 207
Self-citationBody mass index and risk of liver cirrhosis in middle aged UK women: prospective study
Liu, B., Balkwill, A., Reeves, G., Beral, V., & Collaborators., O. B. O. T. M. W. S. (2010) · BMJ · doi:10.1136/bmj.c912 · Cited by 202
Marventano, S., Salomone, F., Godos, J., Pluchinotta, F., Del Rio, D., Mistretta, A., & Grosso, G. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.03.012 · Cited by 197
A pilot study of orlistat treatment in obese, non‐alcoholic steatohepatitis patients
Harrison, S. A., Fincke, C., Helinski, D., Torgerson, S., & Hayashi, P. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02153.x · Cited by 191
White Paper AGA: POWER — Practice Guide on Obesity and Weight Management, Education, and Resources
Acosta, A., Streett, S., Kroh, M. D., Cheskin, L. J., Saunders, K. H., Kurian, M., Schofield, M., Barlow, S. E., & Aronne, L. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.10.023 · Cited by 191
Shibuya, T., Fushimi, N., Kawai, M., Yoshida, Y., Hachiya, H., Ito, S., Kawai, H., Ohashi, N., & Mori, A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13061 · Cited by 191
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
Self-citationShao, N., Kuang, H. Y., Hao, M., Gao, X. Y., Lin, W. J., & Zou, W. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2561 · Cited by 185
Schlesinger, S., Aleksandrova, K., Pischon, T., Fedirko, V., Jenab, M., Trepo, E., Boffetta, P., Dahm, C. C., Overvad, K., Tjønneland, A., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.27645 · Cited by 185
Predictors of Nonalcoholic Steatohepatitis (NASH) in Obese Patients Undergoing Gastric Bypass
Boza, C., Riquelme, A., Ibañez, L., Duarte, I., Norero, E., Viviani, P., Soza, A., Fernandez, J. I., Raddatz, A., Guzman, S., et al. (2005) · Obesity Surgery · doi:10.1381/0960892055002347 · Cited by 183
Eguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., Araki, N., Tanaka, K., Yamaguchi, M., Matsuda, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12351 · Cited by 182 · cited 1×
“approved for obesity in a prospective uncontrolled study [161].”
BackgroundMathew, H., Farr, O. M., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2015.10.019 · Cited by 182
Self-citationChitturi, S., Wong, V. W., Chan, W., Wong, G. L., Wong, S. K., Sollano, J., Ni, Y., Liu, C., Lin, Y., Lesmana, L. A., et al. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13856 · Cited by 182
Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults
Borena, W., Strohmaier, S., Lukanova, A., Bjørge, T., Lindkvist, B., Hallmans, G., Edlinger, M., Stocks, T., Nagel, G., Manjer, J., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.26338 · Cited by 177
New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
Mendez-Sanchez, N., Cruz-Ramon, V. C., Ramirez-Perez, O. L., Hwang, J. P., Barranco-Fragoso, B., & Cordova-Gallardo, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072034 · Cited by 172
Younossi, Z. M., Otgonsuren, M., Venkatesan, C., & Mishra, A. (2013) · Metabolism · doi:10.1016/j.metabol.2012.08.005 · Cited by 169
Sattar, N., Fitchett, D., Hantel, S., George, J. T., & Zinman, B. (2018) · Diabetologia · doi:10.1007/s00125-018-4702-3 · Cited by 168
Nonalcoholic Fatty Liver Disease
Pοlyzos, S. A., Kountouras, J., Zavos, C., & Deretzi, G. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31824587e0 · Cited by 167
Self-citationAssociation of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease
Boutari, C., Perakakis, N., & Mantzoros, C. S. (2018) · Endocrinology and Metabolism · doi:10.3803/enm.2018.33.1.33 · Cited by 167
Self-citationNeutrophil-Hepatic Stellate Cell Interactions Promote Fibrosis in Experimental Steatohepatitis
Zhou, Z., Xu, M.-J., Cai, Y., Wang, W., Jiang, J. X., Varga, Z. V., Feng, D., Pacher, P., Kunos, G., Torok, N. J., et al. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.01.003 · Cited by 164
Feng, W., Gao, C., Bi, Y., Wu, M., Li, P., Shen, S., Chen, W., Yin, T., & Zhu, D. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12555 · Cited by 164
Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease
Hannah, W. N., & Harrison, S. A. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.008 · Cited by 163
A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis
Younossi, Z. M., Page, S., Rafiq, N., Birerdinc, A., Stepanova, M., Hossain, N., Afendy, A., Younoszai, Z., Goodman, Z., & Baranova, A. (2011) · Obesity Surgery · doi:10.1007/s11695-010-0204-1 · Cited by 162
Chang, Y., Cho, Y. K., Kim, Y., Sung, E., Ahn, J., Jung, H., Yun, K. E., Shin, H., & Ryu, S. (2019) · Hepatology · doi:10.1002/hep.30170 · Cited by 162
Body composition phenotypes and obesity paradox
Prado, C. M. M., González, M. C., & Heymsfield, S. B. (2015) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000216 · Cited by 160
Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans
Kanwal, F., Kramer, J. R., Duan, Z., Yu, X., White, D., & El-Serag, H. B. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.08.010 · Cited by 159
Natural History of Nonalcoholic Fatty Liver Disease
Goh, G. B., & McCullough, A. J. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4095-4 · Cited by 159
Adipocytokines and hepatic fibrosis
Saxena, N. K., & Anania, F. A. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.01.002 · Cited by 149
Body mass index in childhood and adult risk of primary liver cancer
Berentzen, T. L., Gamborg, M., Holst, C., Sørensen, T. I. A., & Baker, J. L. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.015 · Cited by 149
Nati, M., Haddad, D., Birkenfeld, A. L., Koch, C. A., Chavakis, T., & Chatzigeorgiou, A. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9339-2 · Cited by 144
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pouwels, P. J. W., Pieters-van den Bos, I. C., Hoekstra, T., Diamant, M., van Raalte, D. H., & Cahen, D. L. (2016) · Diabetologia · doi:10.1007/s00125-016-4100-7 · Cited by 142
Tobita, H., Sato, S., Miyake, T., Ishihara, S., & Kinoshita, Y. (2017) · Current Therapeutic Research · doi:10.1016/j.curtheres.2017.07.002 · Cited by 142
Results of Laparoscopic Gastric Bypass in Patients with Cirrhosis
Dallal, R. M., Mattar, S. G., Lord, J. L., Watson, A. R., Cottam, D. R., Eid, G. M., Hamad, G. G., Rabinovitz, M., & Schauer, P. R. (2004) · Obesity Surgery · doi:10.1381/096089204772787284 · Cited by 140
Smart, N. A., King, N., McFarlane, J. R., Graham, P. L., & Dieberg, G. (2018) · British Journal of Sports Medicine · doi:10.1136/bjsports-2016-096197 · Cited by 140
Effect of canagliflozin on liver function tests in patients with type 2 diabetes
Leiter, L. A., Forst, T. M., Polidori, D., Balis, D. A., Xie, J., & Sha, S. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.10.003 · Cited by 133
Pais, R., Fartoux, L., Goumard, C., Scatton, O., Wendum, D., Rosmorduc, O., & Ratziu, V. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14261 · Cited by 129
A Systematic Review of Bariatric Surgery in Patients with Liver Cirrhosis
Jan, A., Narwaria, M., & Mahawar, K. K. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1727-2 · Cited by 129
Ioannou, G. N., Weiss, N. S., Kowdley, K. V., & Dominitz, J. A. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)01200-9 · Cited by 129
Hajifathalian, K., Torabi Sagvand, B., & McCullough, A. J. (2019) · Hepatology · doi:10.1002/hep.30226 · Cited by 128 · cited 1×
“5 drinks/daywith increased all-causemortality in NAFLD patients comparedwith abstinence from alcohol [147].”
BackgroundEffects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes
Sathyanarayana, P., Jogi, M., Muthupillai, R., Krishnamurthy, R., Samson, S. L., & Bajaj, M. (2011) · Obesity · doi:10.1038/oby.2011.152 · Cited by 124
Fibrosis in Nonalcoholic Fatty Liver Disease: Mechanisms and Clinical Implications
Angulo, P., Machado, M., & Diehl, A. (2015) · Seminars in liver disease (Print) · doi:10.1055/s-0035-1550065 · Cited by 123
Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
Fan, H., Pan, Q., Xu, Y., & Yang, X. (2013) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302013000900005 · Cited by 122
Pοlyzos, S. A., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.05.013 · Cited by 115
Self-citationPharmacological management of nonalcoholic fatty liver disease
Barb, D., Portillo-Sanchez, P., & Cusi, K. (2016) · Metabolism · doi:10.1016/j.metabol.2016.04.004 · Cited by 114 · cited 1×
“Second, other treatments have been also investigated in NASH patients andmuchmore are under investigation, as elsewhere summarized [15,216].”
BackgroundPerumpail, R. B., Wong, R. J., Ahmed, A., & Harrison, S. A. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3821-7 · Cited by 111
Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors
Heiker, J. T., Kosel, D., & Beck‐Sickinger, A. G. (2010) · Biological Chemistry · doi:10.1515/bc.2010.104 · Cited by 109
Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: A case series
Kenny, P. R., Brady, D. E., Torres, D. M., Ragozzino, L., Chalasani, N., & Harrison, S. A. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.363 · Cited by 106
van den Berg, E. H., Amini, M., Schreuder, T. C. M. A., Dullaart, R. P. F., Faber, K. N., Alizadeh, B. Z., & Blokzijl, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171502 · Cited by 106
Wu, Z., Cheng, Y., Gu, W., & Aung, L. H. H. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.001 · Cited by 104
Sookoian, S. C., & Pirola, C. J. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14401 · Cited by 103
Pοlyzos, S. A., Kountouras, J., Deretzi, G., Zavos, C., & Mantzoros, C. S. (2011) · Current Molecular Medicine · doi:10.2174/156652412798376161 · Cited by 101
Self-citationKhoo, J., Hsiang, J., Taneja, R., Law, N., & Ang, T. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13007 · Cited by 99
Recent research trends and updates on nonalcoholic fatty liver disease
Yoo, J., Kim, W. K., Kim, M. Y., Jun, D. W., Kim, S. G., Yeon, J.-E., Lee, J. W., Cho, Y. K., Park, S. H., & Sohn, J. H. (2018) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2018.0037 · Cited by 97
Pοlyzos, S. A., Kountouras, J., Zavos, C., & Deretzi, G. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181ec5c66 · Cited by 96
Self-citationGastaldelli, A., Gaggini, M., Daniele, G., Ciociaro, D., Cersosimo, E., Tripathy, D., Triplitt, C., Fox, P., Musi, N., DeFronzo, R., et al. (2016) · Hepatology · doi:10.1002/hep.28827 · Cited by 96 · cited 1×
“on a dynamic positron emission tomography study, exenatide was shown to decrease both hepatic and adipose tissue IR [168], which are”
BackgroundSeko, Y., Sumida, Y., Tanaka, S., Mori, K., Taketani, H., Ishiba, H., Hara, T., Okajima, A., Umemura, A., Nishikawa, T., et al. (2016) · Hepatology Research · doi:10.1111/hepr.12834 · Cited by 94
Farnesoid X receptor modulators 2014-present: a patent review
Sepe, V., Distrutti, E., Fiorucci, S., & Zampella, A. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1459569 · Cited by 94
Vonghia, L., Magrone, T., Verrijken, A., Michielsen, P. P., Gaal, L. V., Jirillo, E., & Francque, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143380 · Cited by 89
Seko, Y., Sumida, Y., Tanaka, S., Mori, K., Taketani, H., Ishiba, H., Hara, T., Okajima, A., Umemura, A., Nishikawa, T., et al. (2017) · Hepatology Research · doi:10.1111/hepr.12837 · Cited by 89
Origin and function of myofibroblasts in the liver
Schwabe, R., & Wells, R. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1550061 · Cited by 86
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options
Younossi, Z. M., Stepanova, M., Sanyal, A. J., Harrison, S. A., Ratziu, V., Abdelmalek, M. F., Diehl, A. M., Caldwell, S. H., Shiffman, M. L., Schall, R. A., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.08.013 · Cited by 85
Ahn, J., Jun, D. W., Lee, H. Y., & Moon, J. H. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2018.09.022 · Cited by 85
Nonalcoholic fatty future disease
Pοlyzos, S. A., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2015.12.009 · Cited by 83
Self-citationOhki, T., Isogawa, A., Toda, N., & Tagawa, K. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0383-1 · Cited by 82
Adipose tissue inflammation and liver pathology in human obesity
Tordjman, J., Guerre-Millo, M., & Clément, K. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)74601-9 · Cited by 80
González‐Ruíz, K., Ramírez‐Vélez, R., Correa‐Bautista, J. E., Peterson, M. D., & García‐Hermoso, A. (2017) · Childhood Obesity · doi:10.1089/chi.2017.0027 · Cited by 79
Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study
Itani, T., & Ishihara, T. (2018) · Obesity Science & Practice · doi:10.1002/osp4.294 · Cited by 79
Exercise and diet in the management of nonalcoholic fatty liver disease
Mahady, S. E., & George, J. (2015) · Metabolism · doi:10.1016/j.metabol.2015.10.032 · Cited by 76
Takase, T., Nakamura, A., Miyoshi, H., Yamamoto, K., & Atsumi, T. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0295 · Cited by 76
Gerhard, G. S., Legendre, C., Still, C. D., Chu, X., Petrick, A. T., & DiStefano, J. K. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00122 · Cited by 76
Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease
Pοlyzos, S. A., & Mantzoros, C. S. (2013) · Metabolism · doi:10.1016/j.metabol.2013.10.010 · Cited by 74
Self-citationSleeve Gastrectomy Outcomes in Patients with BMI Between 30 and 35–3 Years of Follow-Up
Berry, M. A., Urrutia, L., Lamoza, P., Molina, A., Luna, E., Parra, F., Domínguez, M. J., & Rodrigo Alonso, K. (2017) · Obesity Surgery · doi:10.1007/s11695-017-2897-x · Cited by 73
Leptin in Health and Disease: Facts and Expectations at its Twentieth Anniversary
Pοlyzos, S. A., & Mantzoros, C. S. (2014) · Metabolism · doi:10.1016/j.metabol.2014.10.017 · Cited by 71
Self-citationAggressive non-alcoholic steatohepatitis following rapid weight loss and/or malnutrition
Tsai, J., Ferrell, L. D., Tan, V. S., Yeh, M. M., Sarkar, M. A., & Gill, R. M. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.13 · Cited by 71
Seko, Y., Sumida, Y., Sasaki, K., Itoh, Y., Iijima, H., Hashimoto, T., Ishii, S., & Inagaki, N. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1364-8 · Cited by 71
Efficacy of orlistat in non‑alcoholic fatty liver disease: A systematic review and meta‑analysis
Wang, H., Wang, L., Cheng, Y., Xia, Z., Liao, Y., & Cao, J. (2018) · Biomedical Reports · doi:10.3892/br.2018.1100 · Cited by 70
Liver fibrosis: the 2017 state of art
Caviglia, G. P., Rosso, C., Fagoonee, S., Saracco, G. M., & Pellicano, R. (2017) · Panminerva Medica · doi:10.23736/s0031-0808.17.03359-6 · Cited by 68
Weight reduction for non-alcoholic fatty liver disease
Peng, L., Wang, J., & Li, F. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003619.pub3 · Cited by 67
Childhood predictors of adult fatty liver. The Cardiovascular Risk in Young Finns Study
Suomela, E., Oikonen, M., Pitkänen, N., Ahola‐Olli, A., Virtanen, J. M., Parkkola, R. K., Jokinen, E. V., Laitinen, T. P., Hutri‐Kähönen, N., Kähönen, M. A. P., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.020 · Cited by 67
The Biological Clock: A Pivotal Hub in Non-alcoholic Fatty Liver Disease Pathogenesis
Mazzoccoli, G., Cosmo, S. D., & Mazza, T. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00193 · Cited by 66
Otgonsuren, M., Stepanova, M., Gerber, L. H., & Younossi, Z. M. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2446-3 · Cited by 64
Goossens, N., Hoshida, Y., Song, W., Jung, M. K., Morel, P., Nakagawa, S., Zhang, B., Frossard, J., Spahr, L., Friedman, S. L., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.10.010 · Cited by 62
Kim, D., Kim, W. K., Joo, S. K., Kim, J. H., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2018) · Liver International · doi:10.1111/liv.13983 · Cited by 62
Gluud, L. L., Knop, F. K., & Vilsbøll, T. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005325 · Cited by 59
BAJAJ, H. S., Brown, R. E., Bhullar, L., Sohi, N., Kalra, S., & Aronson, R. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.08.001 · Cited by 54
Emerging and future therapies for nonalcoholic steatohepatitis in adults
Mintziori, G., & Pοlyzos, S. A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1225727 · Cited by 53
Long-term weight control study V (weeks 190 to 210)
WEINTRAUB, M. I., Sundaresan, P. R., Schuster, B., Averbuch, M., Stein, E., & Byrne, L. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.73 · Cited by 52
Inflammation: A key player linking obesity with malignancies
Boutari, C., & Mantzoros, C. S. (2018) · Metabolism · doi:10.1016/j.metabol.2017.12.015 · Cited by 52
Self-citationChoi, D., Jung, C., Mok, J., Kim, C., Kang, S.-K., & Kim, B. (2018) · Endocrinology and Metabolism · doi:10.3803/enm.2018.33.3.387 · Cited by 50
Assy, N., Hussein, O., & Abassi, Z. A. (2007) · Gut · doi:10.1136/gut.2006.106021 · Cited by 48
McCarty, T. R., Echouffo-Tcheugui, J. B., Lange, A., Haque, L., & Njei, B. M. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.09.511 · Cited by 47
Magkos, F., & Mantzoros, C. S. (2010) · Metabolism · doi:10.1016/j.metabol.2010.09.011 · Cited by 46
Self-citation
Research works printed but not linked: 3
- Polyzos, 2009, The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in nonalcoholic fatty liver disease, Hippokratia, 13, 127
- Kim, 2018, Non-alcoholic fatty liver disease in obese and non-obese pediatric patients, Korean J Pediatr
- Cotler, 2004, Hepatic decompensation after gastric bypass surgery for severe obesity, Dig Dis Sci, 49, 1563, 10.1023/B:DDAS.0000043364.75898.c8 · doi:10.1023/b:ddas.0000043364.75898.c8
Cited by
Non-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
Quek, J., Chan, K. E., Wong, Z. Y., Tan, C., Tan, B., Lim, W. H., Tan, D. J. H., Tang, A. S. P., Tay, P., Xiao, J., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00317-x · Cited by 749
NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes
Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00570-y · Cited by 643
Kanwal, F., Shubrook, J. H., Adams, L. A., Pfotenhauer, K., Wai-Sun Wong, V., Wright, E., Abdelmalek, M. F., Harrison, S. A., Loomba, R., Mantzoros, C. S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.049 · Cited by 618
Self-citation
Metadata
- Authors
- Polyzos, S. A., Kountouras, J., & Mantzoros, C. S.
- Venue
- Metabolism
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 92
- Pages
- 82-97
- ISSN
- 0026-0495 (ISSN-L)
- OpenAlex
- W2902419609
- Cited by
- 1,211
- References
- 219
- FWCI
- 46.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.